KR100529980B1 - 신규 에리트로마이신 유도체, 그의 제조 방법 및 의약으로서의용도 - Google Patents
신규 에리트로마이신 유도체, 그의 제조 방법 및 의약으로서의용도 Download PDFInfo
- Publication number
- KR100529980B1 KR100529980B1 KR10-1999-7007791A KR19997007791A KR100529980B1 KR 100529980 B1 KR100529980 B1 KR 100529980B1 KR 19997007791 A KR19997007791 A KR 19997007791A KR 100529980 B1 KR100529980 B1 KR 100529980B1
- Authority
- KR
- South Korea
- Prior art keywords
- radicals
- radical
- carbon atoms
- aryl
- formula
- Prior art date
Links
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical class O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 title claims description 38
- 238000000034 method Methods 0.000 title claims description 10
- 238000002360 preparation method Methods 0.000 title claims description 8
- 239000003814 drug Substances 0.000 title description 7
- 229940079593 drug Drugs 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 39
- 125000003118 aryl group Chemical group 0.000 claims abstract description 20
- 150000003839 salts Chemical class 0.000 claims abstract description 17
- 125000005842 heteroatom Chemical group 0.000 claims abstract description 13
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract description 11
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 6
- 125000004429 atom Chemical group 0.000 claims abstract description 5
- -1 heteroaryl radical Chemical class 0.000 claims description 106
- 125000004432 carbon atom Chemical group C* 0.000 claims description 49
- 150000003254 radicals Chemical class 0.000 claims description 44
- 239000000203 mixture Substances 0.000 claims description 21
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 20
- 229960003276 erythromycin Drugs 0.000 claims description 19
- 150000005840 aryl radicals Chemical class 0.000 claims description 17
- 125000005740 oxycarbonyl group Chemical group [*:1]OC([*:2])=O 0.000 claims description 16
- 125000005638 hydrazono group Chemical group 0.000 claims description 15
- 125000001424 substituent group Chemical group 0.000 claims description 12
- 150000002923 oximes Chemical class 0.000 claims description 11
- 125000005843 halogen group Chemical group 0.000 claims description 10
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 9
- SZPWXAOBLNYOHY-UHFFFAOYSA-N [C]1=CC=NC2=CC=CC=C12 Chemical group [C]1=CC=NC2=CC=CC=C12 SZPWXAOBLNYOHY-UHFFFAOYSA-N 0.000 claims description 8
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 8
- 125000003342 alkenyl group Chemical group 0.000 claims description 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 7
- 239000002253 acid Substances 0.000 claims description 6
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 229920006395 saturated elastomer Polymers 0.000 claims description 6
- 125000004434 sulfur atom Chemical group 0.000 claims description 6
- 239000004480 active ingredient Substances 0.000 claims description 5
- 125000002252 acyl group Chemical group 0.000 claims description 4
- 125000003302 alkenyloxy group Chemical group 0.000 claims description 4
- 125000005108 alkenylthio group Chemical group 0.000 claims description 4
- 125000003545 alkoxy group Chemical group 0.000 claims description 4
- 125000004414 alkyl thio group Chemical group 0.000 claims description 4
- 125000005133 alkynyloxy group Chemical group 0.000 claims description 4
- 125000005109 alkynylthio group Chemical group 0.000 claims description 4
- 125000004104 aryloxy group Chemical group 0.000 claims description 4
- 125000002837 carbocyclic group Chemical group 0.000 claims description 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 4
- 125000002950 monocyclic group Chemical group 0.000 claims description 4
- 150000003457 sulfones Chemical class 0.000 claims description 4
- 150000003462 sulfoxides Chemical class 0.000 claims description 4
- 125000004659 aryl alkyl thio group Chemical group 0.000 claims description 3
- 125000005110 aryl thio group Chemical group 0.000 claims description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 3
- 229910052736 halogen Inorganic materials 0.000 claims description 3
- 150000002367 halogens Chemical class 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- 125000000304 alkynyl group Chemical group 0.000 claims description 2
- 125000000539 amino acid group Chemical group 0.000 claims description 2
- 125000002102 aryl alkyloxo group Chemical group 0.000 claims description 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 2
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 2
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims description 2
- 125000001188 haloalkyl group Chemical group 0.000 claims description 2
- 125000000623 heterocyclic group Chemical group 0.000 claims description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 2
- 239000012434 nucleophilic reagent Substances 0.000 claims description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
- 125000001453 quaternary ammonium group Chemical group 0.000 claims description 2
- 238000007142 ring opening reaction Methods 0.000 claims description 2
- DCRUFAPMHZEKBW-UHFFFAOYSA-N thiocyanatoformic acid Chemical compound OC(=O)SC#N DCRUFAPMHZEKBW-UHFFFAOYSA-N 0.000 claims description 2
- 230000000845 anti-microbial effect Effects 0.000 claims 3
- 230000009286 beneficial effect Effects 0.000 abstract 1
- 230000003115 biocidal effect Effects 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 48
- 239000000047 product Substances 0.000 description 45
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 42
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 33
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 24
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 20
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 16
- 239000000908 ammonium hydroxide Substances 0.000 description 16
- 239000000243 solution Substances 0.000 description 16
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 15
- 239000000377 silicon dioxide Substances 0.000 description 12
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 10
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 8
- 229940126062 Compound A Drugs 0.000 description 8
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 8
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 8
- 238000004587 chromatography analysis Methods 0.000 description 8
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 6
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 239000003480 eluent Substances 0.000 description 5
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 5
- 235000019341 magnesium sulphate Nutrition 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 239000000460 chlorine Substances 0.000 description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 125000006201 3-phenylpropyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 206010041925 Staphylococcal infections Diseases 0.000 description 3
- 229960000583 acetic acid Drugs 0.000 description 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 229910052763 palladium Inorganic materials 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 125000004483 piperidin-3-yl group Chemical group N1CC(CCC1)* 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 229940093915 gynecological organic acid Drugs 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- KYTWXIARANQMCA-PGYIPVOXSA-N (3r,4s,5s,6r,7r,9r,10z,11s,12r,13s,14r)-6-[(2s,3r,4s,6r)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-14-ethyl-7,12,13-trihydroxy-10-hydroxyimino-4-[(2r,4r,5s,6s)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-3,5,7,9,11,13-hexamethyl-oxacyclotetradec Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=N\O)/[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 KYTWXIARANQMCA-PGYIPVOXSA-N 0.000 description 1
- KKFDJZZADQONDE-UHFFFAOYSA-N (hydridonitrato)hydroxidocarbon(.) Chemical compound O[C]=N KKFDJZZADQONDE-UHFFFAOYSA-N 0.000 description 1
- RVHOBHMAPRVOLO-UHFFFAOYSA-N 2-ethylbutanedioic acid Chemical compound CCC(C(O)=O)CC(O)=O RVHOBHMAPRVOLO-UHFFFAOYSA-N 0.000 description 1
- IQVAERDLDAZARL-UHFFFAOYSA-N 2-phenylpropanal Chemical compound O=CC(C)C1=CC=CC=C1 IQVAERDLDAZARL-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- GAMYYCRTACQSBR-UHFFFAOYSA-N 4-azabenzimidazole Chemical compound C1=CC=C2NC=NC2=N1 GAMYYCRTACQSBR-UHFFFAOYSA-N 0.000 description 1
- AGNFWIZBEATIAK-UHFFFAOYSA-N 4-phenylbutylamine Chemical compound NCCCCC1=CC=CC=C1 AGNFWIZBEATIAK-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 241000193738 Bacillus anthracis Species 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 201000004813 Bronchopneumonia Diseases 0.000 description 1
- 206010006500 Brucellosis Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000606161 Chlamydia Species 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 241000606768 Haemophilus influenzae Species 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical group C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000589248 Legionella Species 0.000 description 1
- 208000007764 Legionnaires' Disease Diseases 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000202934 Mycoplasma pneumoniae Species 0.000 description 1
- 208000005141 Otitis Diseases 0.000 description 1
- 208000035109 Pneumococcal Infections Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- NBBJYMSMWIIQGU-UHFFFAOYSA-N Propionic aldehyde Chemical compound CCC=O NBBJYMSMWIIQGU-UHFFFAOYSA-N 0.000 description 1
- 241000606701 Rickettsia Species 0.000 description 1
- 206010039587 Scarlet Fever Diseases 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- 241000295644 Staphylococcaceae Species 0.000 description 1
- 206010056430 Staphylococcal sepsis Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 206010061372 Streptococcal infection Diseases 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 241000534944 Thia Species 0.000 description 1
- 241000223996 Toxoplasma Species 0.000 description 1
- 241000202898 Ureaplasma Species 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- YUDRVAHLXDBKSR-UHFFFAOYSA-N [CH]1CCCCC1 Chemical compound [CH]1CCCCC1 YUDRVAHLXDBKSR-UHFFFAOYSA-N 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 1
- 150000001241 acetals Chemical class 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 125000005336 allyloxy group Chemical group 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 125000004744 butyloxycarbonyl group Chemical group 0.000 description 1
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 229940043264 dodecyl sulfate Drugs 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 208000019258 ear infection Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 125000005290 ethynyloxy group Chemical group C(#C)O* 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000005928 isopropyloxycarbonyl group Chemical group [H]C([H])([H])C([H])(OC(*)=O)C([H])([H])[H] 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 229940098895 maleic acid Drugs 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 238000006140 methanolysis reaction Methods 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 125000006216 methylsulfinyl group Chemical group [H]C([H])([H])S(*)=O 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000002687 nonaqueous vehicle Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- HYDZPXNVHXJHBG-UHFFFAOYSA-N o-benzylhydroxylamine;hydron;chloride Chemical compound Cl.NOCC1=CC=CC=C1 HYDZPXNVHXJHBG-UHFFFAOYSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- ORTFAQDWJHRMNX-UHFFFAOYSA-M oxidooxomethyl Chemical compound [O-][C]=O ORTFAQDWJHRMNX-UHFFFAOYSA-M 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004742 propyloxycarbonyl group Chemical group 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 description 1
- 239000012429 reaction media Substances 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229960001367 tartaric acid Drugs 0.000 description 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 238000002834 transmittance Methods 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 235000019871 vegetable fat Nutrition 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
- C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Abstract
Description
Claims (17)
- 화학식 I의 화합물 또는 그의 산부가염.<화학식 I>상기 식에서,A 및 B는 이들이 결합된 원자들과 함께 기 [여기서, R1은 NH2 라디칼, 또는 탄소 원자수 18개 이하인 NH-알킬, NH-알케닐 또는 NH-알키닐 라디칼, 또는 NH(CH2)nAr 또는 N=CH(CH2)nAr 라디칼 (여기서, n은 정수 1 내지 6이고, Ar은 치환되거나 치환되지 않은 아릴 또는 헤테로아릴 라디칼을 나타냄)을 나타냄]를 형성하고,Z는 수소 원자를 나타내거나 탄소 원자수 18개 이하인 카르복실산의 잔기를 나타내고,R은 - 수소 원자,- 질소 원자 1개 이상과 선택적으로 또다른 이종 원자를 함유하고, 12원 이하로 이루어지며, 질소 원자 상에서 치환되거나 치환되지 않은 방향족 또는 비방향족, 포화 또는 불포화된 1환 또는 2환 헤테로시클릭 라디칼,- 히드록실, 할로겐, 시아노, 니트로, 아미디닐, 구아니디닐, 앞서 정의된 것과 같은 헤테로시클릭; 탄소 원자수 6개 이하의 알킬옥시, 알케닐옥시 또는 알키닐옥시; 탄소 원자수가 6개 이하이고 황 원자가 경우에 따라 술폭시드 또는 술폰으로 산화된 알킬티오, 알케닐티오 또는 알키닐티오; 아릴, 아르알킬; 아릴옥시, 아르알킬옥시; 황 원자가 경우에 따라 술폭시드 또는 술폰으로 산화된 아릴티오 및 아르알킬티오; 기 (여기서, R'1 및 R'2는 동일하거나 상이하며, 수소 원자, 탄소 원자수 18개 이하의 직쇄, 분지쇄 또는 시클릭 알킬, 알케닐 또는 알키닐 라디칼, 아릴 또는 아르알킬 라디칼을 나타내고, 이들 R'1 및 R'2 라디칼 각각은 히드록시, 탄소 원자수 8개 이하의 알킬옥시, 알케닐옥시, 알키닐옥시, 알킬티오, 알케닐티오 또는 알키닐티오, 아미노, 탄소 원자수 4개 이하의 모노알킬아미노, 탄소 원자수 8개 이하의 디알킬아미노, 시아노, 유리 상태이거나, 에스테르화되거나 염 형태인 탄소 원자수 8개 이하의 카르복시, 아실 또는 카르바모일 라디칼 하나 이상에 의해, Si(alk)3 또는 Si(Oalk)3 (여기서, alk는 탄소 원자수 4개 이하의 알킬 라디칼을 나타냄)에 의해, 또는 앞서 정의된 것과 같은 헤테로시클릭 라디칼에 의해 치환되거나 치환되지 않을 수 있고; 또는 R'1 및 R'2는 이들이 결합된 질소 원자와 함께 선택적으로 또다른 이종 원자를 함유하고 12원 이하인 방향족 또는 비방향족, 포화 또는 불포화된 1환 또는 2환 헤테로시클릭 라디칼을 형성함); 사차 암모늄기; 1,2-에폭시에틸 또는 2,2-디메틸 1,2-에폭시에틸, 또는 친핵 시약에 의해 이들 기가 개환되어 생성된 라디칼; 기 (여기서, B1은 탄소 원자수 6개 이하의 알킬 또는 알킬옥시 라디칼, 또는 아릴, 아르알킬, 아릴옥시 또는 아르알킬옥시 라디칼임); 유리 상태이거나 보호된 포르밀, 유리 상태이거나, 에스테르화되거나 염 형태인 카르복시, 티오시아네이트, 아실 또는 카르바모일; (CH2)nR' (여기서, R'은 아미노산 잔기를 나타내고, n은 정수 0 내지 6임)의 군으로부터 선택된 하나 이상의 기로 치환되거나 치환되지 않은, 탄소 원자수 18개 이하의 직쇄, 분지쇄 또는 시클릭 알킬, 알케닐 또는 알키닐 라디칼을 나타낸다.
- 제1항에 있어서, Z가 수소 원자인 화학식 I의 화합물.
- 제1항 또는 제2항에 있어서, R1이 NH(CH2)nAr 라디칼이고, n 및 Ar이 제1항에서와 같은 의미를 가지는 화학식 I의 화합물.
- 제1항 또는 제2항에 있어서, Ar이라디칼 (여기서, X는 수소 원자, CH3, OH, OMe 라디칼 또는 할로겐 원자임)인 화학식 I의 화합물.
- 제4항에 있어서, Ar이 라디칼인 화학식 I의 화합물.
- 제3항에 있어서, n이 3인 화학식 I의 화합물.
- 제1항에 있어서, R이 - 수소 원자,- 라디칼, 또는- [이 라디칼은 라디칼 {여기서, m은 정수 0 내지 20을 나타내고, n은 정수 0 내지 3을 나타내고, A 및 B는 동일하거나 상이하며, 수소 원자, 할로겐 원자, 또는 탄소 원자수 8개 이하의 알킬 또는 아릴 라디칼을 나타내고 이중 결합의 기하 구조가 E 또는 Z, 또는 E+Z 혼합물이거나, 또는 A 및 B가 이들이 결합된 탄소 원자들 사이의 추가 결합을 형성하고, XA는 이종 원자 하나 이상이 삽입되거나 삽입되지 않았고 하나 이상의 할로겐 원자에 의해 치환되거나 치환되지 않은 탄소 원자수 6 내지 20개의 포화 또는 불포화된 직쇄 또는 분지쇄 알킬 라디칼; 카르보시클릭 아릴 라디칼에 의해 치환되거나 치환되지 않은 탄소 원자수 3 내지 8개의 시클릭 알킬 라디칼; 할로겐 원자; C≡N 라디칼; OR3, COR4, CO2R5, SR6, , SO2R8 또는 라디칼 (여기서, R3, R4, R5, R6, R7, R8 및 R9은 수소 원자; 탄소 원자수 8개 이하이고, 이종 원자 하나 이상이 삽입되거나 삽입되지 않았고 할로겐 원자 하나 이상으로 치환되거나 치환되지 않은 알킬 라디칼; 유리 상태이거나, 염 형태이거나, 에스테르화되었거나 아미드화된 카르복시 라디칼, 히드록실 라디칼, 할로겐 원자, NO2 라디칼, C≡N 라디칼, 탄소 원자수 12개 이하이고 할로겐 원자 하나 이상으로 치환되거나 치환되지 않은 알킬, 알케닐 및 알키닐, O-알킬, O-알케닐 및 O-알키닐, S-알킬, S-알케닐 및 S-알키닐, SO-알킬, SO-알케닐 및 SO-알키닐, SO2-알킬, SO2-알케닐 및 SO2-알키닐 라디칼, 탄소 원자수 14개 이하의 카르보시클릭 또는 헤테로시클릭 아릴, O-아릴, S-아릴 라디칼, 라디칼 (여기서, R'1 및 R'2는 동일하거나 상이하고, 수소 원자를 나타내거나 탄소 원자수 12개 이하의 알킬 라디칼, 아릴 라디칼에 대한 상기 치환체 중 하나에 의해 자체가 치환되거나 치환되지 않은 아릴 라디칼을 나타냄)로 구성되는 군으로부터 선택된 하나 이상의 라디칼로 치환되거나 치환되지 않은 탄소 원자수 14개 이하의 카르보시클릭 또는 헤테로시클릭 아릴 또는 아르알킬 라디칼을 나타냄); NR1R2 라디칼 (여기서, R1 및 R2는 동일하거나 상이하고, 수소 원자이거나 탄소 원자수 20개 이하의 알킬 라디칼, 탄소 원자수 8개 이하의 -CO-알킬 또는 -CO2-알킬, 또는 탄소 원자수 14개 이하의 아릴, -CO-아릴 또는 -CO2-아릴, 또는 아르알킬, -CO-아르알킬 또는 -CO2-아르알킬 라디칼 (여기서, 아릴 라디칼은 아릴 라디칼에 대한 상기 치환체들 중 하나에 의해 자체가 치환되었거나 치환되지 않았음)이거나, 또는 R1 및 R2는 이들이 결합된 질소 원자와 함께 또다른 이종 원자를 함유하거나 함유하지 않고 아릴 라디칼에 대한 상기 치환체들 중 하나에 의해 치환되거나 치환되지 않은 3 내지 8원의 고리를 형성함); 아릴 라디칼에 대한 상기 치환체들 중 하나 이상으로 치환되거나 치환되지 않은 카르보시클릭 아릴 라디칼; 아릴 라디칼에 대한 상기 치환체들 중 하나 이상으로 치환되거나 치환되지 않았고 이종 원자 1개 이상을 함유하는 헤테로시클릭 아릴 라디칼; 또는 OC(Ar)3 라디칼 (여기서, Ar은 아릴 라디칼에 대한 상기 치환체들 중 하나 이상으로 치환되거나 치환되지 않은 카르보시클릭 아릴 라디칼을 나타냄)을 나타냄}에 의해 질소 원자 상에서 치환되거나 치환되지 않을 수 있음]인 화학식 I의 화합물.
- 제1항에 있어서, 화합물명이 11,12-디데옥시-3-데[(2,6-디데옥시-3-C-메틸-3-O-메틸-알파-L-리보헥소피라노실)옥시]-6-O-메틸-3-옥소-12,11-[옥시카르보닐[[3-(4-퀴놀리닐)프로필]히드라조노]]에리트로마이신의 (9E) 9-[O-(3-피페리디닐)옥심]인 화학식 I의 화합물.
- 삭제
- 삭제
- 제1항, 제2항 및 제5항 내지 제8항 중 어느 한 항에 정의된 화합물 1종 이상을 활성 성분으로 함유하는, 항균 활성을 갖는 제약 조성물.
- 화학식 II의 화합물을 화학식 III의 화합물로 처리하여 화학식 I의 대응 화합물을 얻고, 2' 위치에서 히드록실이 드러나게 하는 것을 특징으로 하는, 제1항에서 정의된 화학식 I의 화합물의 제조 방법.<화학식 II><화학식 III>H2NOR상기 식들에서,A, B, R 및 Z는 제1항에서 정의된 것과 같다.
- 제12항에 있어서, 얻은 화학식 I의 화합물을 산의 작용으로 염을 형성하는 것을 특징으로 하는, 제1항에서 정의된 화학식 I의 화합물의 제조 방법.
- 제12항에 있어서, 얻은 화학식 I의 화합물을 라디칼을 수식하는 물질로 처리하는 것을 특징으로 하는, 제1항에서 정의된 화학식 I의 화합물의 제조 방법.
- 제12항에 있어서, 얻은 화학식 I의 화합물을 산의 작용으로 염을 형성하고 R 라디칼을 수식하는 물질로 처리하는 것을 특징으로 하는, 제1항에서 정의된 화학식 I의 화합물의 제조 방법.
- 제3항에 정의된 화합물 1종 이상을 활성 성분으로 함유하는, 항균 활성을 갖는 제약 조성물.
- 제4항에 정의된 화합물 1종 이상을 활성 성분으로 함유하는, 항균 활성을 갖는 제약 조성물.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9702352A FR2760017B1 (fr) | 1997-02-27 | 1997-02-27 | Nouveaux derives de l'erytromycine, leur procede de preparation et leur application comme medicaments |
FR97/02352 | 1997-02-27 | ||
PCT/FR1998/000378 WO1998038199A1 (fr) | 1997-02-27 | 1998-02-26 | Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20000075722A KR20000075722A (ko) | 2000-12-26 |
KR100529980B1 true KR100529980B1 (ko) | 2005-11-22 |
Family
ID=9504247
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR10-1999-7007791A KR100529980B1 (ko) | 1997-02-27 | 1998-02-26 | 신규 에리트로마이신 유도체, 그의 제조 방법 및 의약으로서의용도 |
Country Status (21)
Country | Link |
---|---|
EP (1) | EP0968222B1 (ko) |
JP (1) | JP4531136B2 (ko) |
KR (1) | KR100529980B1 (ko) |
CN (1) | CN1162442C (ko) |
AT (1) | ATE219097T1 (ko) |
AU (1) | AU728182B2 (ko) |
BR (1) | BR9807795A (ko) |
CA (1) | CA2282666C (ko) |
DE (1) | DE69805981T2 (ko) |
DK (1) | DK0968222T3 (ko) |
EA (1) | EA002359B1 (ko) |
ES (1) | ES2179475T3 (ko) |
FR (1) | FR2760017B1 (ko) |
HU (1) | HUP0001245A3 (ko) |
IL (1) | IL131340A0 (ko) |
NO (1) | NO315653B1 (ko) |
PL (1) | PL187947B1 (ko) |
PT (1) | PT968222E (ko) |
TR (1) | TR199902092T2 (ko) |
WO (1) | WO1998038199A1 (ko) |
ZA (1) | ZA981482B (ko) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2782239A1 (fr) | 1998-08-13 | 2000-02-18 | Euromark | Benne a racleur integre pour la distribution de produits destines a l'elevage |
ES2243066T3 (es) | 1998-09-22 | 2005-11-16 | Pfizer Products Inc. | Antibioticos de carbamato y carbazato cetolida. |
SI1147121T1 (en) | 1999-01-27 | 2004-04-30 | Pfizer Products Inc. | Ketolide antibiotics |
MXPA01010524A (es) * | 1999-04-16 | 2002-03-14 | Kosan Biosciences Inc | Agentes macrolidos anti-infecciosos. |
EE200100613A (et) | 1999-05-24 | 2003-02-17 | Pfizer Products Inc. | 13-metüülerütromütsiini derivaadid |
ID27331A (id) * | 1999-09-29 | 2001-03-29 | Pfizer Prod Inc | Pembuatan antibiotik-antibiotik ketolida karbamat |
US6673774B2 (en) | 2001-12-03 | 2004-01-06 | Enanta Pharmaceuticals, Inc. | 11-O-substituted macrolides and their descladinose derivatives |
US6670331B2 (en) | 2001-12-04 | 2003-12-30 | Enanta Pharmaceuticals, Inc. | 11-O-substituted ketolide derivatives |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5439889A (en) * | 1993-03-09 | 1995-08-08 | Roussel Uclaf | Erythromycin derivatives |
US5444051A (en) * | 1990-11-21 | 1995-08-22 | Roussel Uclaf | Erythromycin compounds |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2473525A1 (fr) * | 1980-01-11 | 1981-07-17 | Roussel Uclaf | Nouvelles oximes derivees de l'erythromycine, leur procede de preparation et leur application comme medicaments |
US5527780A (en) * | 1992-11-05 | 1996-06-18 | Roussel Uclaf | Erythromycin derivatives |
FR2718450B1 (fr) * | 1994-04-08 | 1997-01-10 | Roussel Uclaf | Nouveaux dérivés de l'érythromycine, leur procédé de préparation et leur application comme médicaments. |
FR2719587B1 (fr) * | 1994-05-03 | 1996-07-12 | Roussel Uclaf | Nouveaux dérivés de l'érythromycine, leur procédé de préparation et leur application comme médicaments. |
-
1997
- 1997-02-27 FR FR9702352A patent/FR2760017B1/fr not_active Expired - Fee Related
-
1998
- 1998-02-23 ZA ZA981482A patent/ZA981482B/xx unknown
- 1998-02-26 DK DK98912554T patent/DK0968222T3/da active
- 1998-02-26 CN CNB988027623A patent/CN1162442C/zh not_active Expired - Lifetime
- 1998-02-26 DE DE69805981T patent/DE69805981T2/de not_active Expired - Lifetime
- 1998-02-26 CA CA002282666A patent/CA2282666C/fr not_active Expired - Lifetime
- 1998-02-26 EP EP98912554A patent/EP0968222B1/fr not_active Expired - Lifetime
- 1998-02-26 HU HU0001245A patent/HUP0001245A3/hu unknown
- 1998-02-26 JP JP53738298A patent/JP4531136B2/ja not_active Expired - Lifetime
- 1998-02-26 BR BR9807795-3A patent/BR9807795A/pt not_active Application Discontinuation
- 1998-02-26 EA EA199900765A patent/EA002359B1/ru not_active IP Right Cessation
- 1998-02-26 ES ES98912554T patent/ES2179475T3/es not_active Expired - Lifetime
- 1998-02-26 IL IL13134098A patent/IL131340A0/xx not_active IP Right Cessation
- 1998-02-26 WO PCT/FR1998/000378 patent/WO1998038199A1/fr not_active Application Discontinuation
- 1998-02-26 TR TR1999/02092T patent/TR199902092T2/xx unknown
- 1998-02-26 PT PT98912554T patent/PT968222E/pt unknown
- 1998-02-26 PL PL33537598A patent/PL187947B1/pl not_active IP Right Cessation
- 1998-02-26 KR KR10-1999-7007791A patent/KR100529980B1/ko not_active IP Right Cessation
- 1998-02-26 AU AU67347/98A patent/AU728182B2/en not_active Expired
- 1998-02-26 AT AT98912554T patent/ATE219097T1/de active
-
1999
- 1999-08-27 NO NO19994150A patent/NO315653B1/no not_active IP Right Cessation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5444051A (en) * | 1990-11-21 | 1995-08-22 | Roussel Uclaf | Erythromycin compounds |
US5439889A (en) * | 1993-03-09 | 1995-08-08 | Roussel Uclaf | Erythromycin derivatives |
Also Published As
Publication number | Publication date |
---|---|
ES2179475T3 (es) | 2003-01-16 |
ZA981482B (en) | 1999-02-23 |
JP2001513101A (ja) | 2001-08-28 |
AU728182B2 (en) | 2001-01-04 |
CN1162442C (zh) | 2004-08-18 |
ATE219097T1 (de) | 2002-06-15 |
PL335375A1 (en) | 2000-04-25 |
HUP0001245A1 (hu) | 2000-09-28 |
WO1998038199A1 (fr) | 1998-09-03 |
FR2760017B1 (fr) | 1999-04-30 |
EA199900765A1 (ru) | 2000-04-24 |
CA2282666A1 (fr) | 1998-09-03 |
NO994150D0 (no) | 1999-08-27 |
FR2760017A1 (fr) | 1998-08-28 |
IL131340A0 (en) | 2001-01-28 |
EP0968222A1 (fr) | 2000-01-05 |
NO994150L (no) | 1999-08-27 |
CN1248261A (zh) | 2000-03-22 |
AU6734798A (en) | 1998-09-18 |
HUP0001245A3 (en) | 2003-05-28 |
NO315653B1 (no) | 2003-10-06 |
DE69805981D1 (de) | 2002-07-18 |
TR199902092T2 (xx) | 2000-05-22 |
CA2282666C (fr) | 2008-09-02 |
DK0968222T3 (da) | 2002-10-07 |
PT968222E (pt) | 2002-10-31 |
KR20000075722A (ko) | 2000-12-26 |
PL187947B1 (pl) | 2004-11-30 |
EP0968222B1 (fr) | 2002-06-12 |
DE69805981T2 (de) | 2003-01-16 |
BR9807795A (pt) | 2000-02-15 |
EA002359B1 (ru) | 2002-04-25 |
JP4531136B2 (ja) | 2010-08-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3130097B2 (ja) | 新規なエリスロマイシン誘導体、その製造法、得られる新規な中間体及びそれらの薬剤としての使用 | |
KR100486053B1 (ko) | 신규에리트로마이신유도체,그의제조방법및약제로서의그의용도 | |
KR100529980B1 (ko) | 신규 에리트로마이신 유도체, 그의 제조 방법 및 의약으로서의용도 | |
JP4573925B2 (ja) | 新規のエリスロマイシン誘導体、その製造方法及びその薬剤としての使用 | |
AP997A (en) | Novel erythromycin derivatives, method for preparing them and their use as medicine. | |
JP2000128896A (ja) | 5―デスオサミニルエリスロノリドaの新規の2―ハロゲン化誘導体、それらの製造方法及び薬剤としてのそれらの使用 | |
MXPA99007812A (en) | Novel erythromycin derivatives, method of preparation and application as medicines | |
KR20000062286A (ko) | 신규한 에리트로마이신 유도체, 제조 방법 및 의약품으로서 용도 | |
USRE38520E1 (en) | Erythromycin derivatives, method for preparing same, and use thereof as drugs | |
EA003776B1 (ru) | Производные 6-деоксиэритромицина, способ их получения и их применение в качестве лекарственных средств | |
MXPA99005226A (en) | Novel erythromycin derivatives, method for preparing them and their use as medicine | |
CZ305199A3 (cs) | Nové deriváty erythromycinu, způsob jejich přípravy a jejich použití jako léčiv |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
N231 | Notification of change of applicant | ||
E902 | Notification of reason for refusal | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20121019 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20131017 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20141022 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20151016 Year of fee payment: 11 |
|
FPAY | Annual fee payment |
Payment date: 20161019 Year of fee payment: 12 |
|
FPAY | Annual fee payment |
Payment date: 20171018 Year of fee payment: 13 |
|
EXPY | Expiration of term |